Drug being tested to reduce cardiovascular events increased risk of heart attack

Patients with acute coronary syndrome who were treated with the experimental drug varespladib were more likely to experience additional cardiovascular events -- including sudden death, heart attack and stroke -- than those treated with placebo, according to research.